{"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David A. Ricks", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 4416885, "fmt": "4.42M", "longFmt": "4,416,885"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anat  Ashkenazi", "age": 50, "title": "Executive VP & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 2125270, "fmt": "2.13M", "longFmt": "2,125,270"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.", "age": 50, "title": "EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 2716346, "fmt": "2.72M", "longFmt": "2,716,346"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anat  Hakim J.D.", "age": 54, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 1979674, "fmt": "1.98M", "longFmt": "1,979,674"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Patrik  Jonsson", "age": 56, "title": "EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 1673270, "fmt": "1.67M", "longFmt": "1,673,270"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Donald A. Zakrowski", "title": "Chief Accounting Officer & VP of Finance", "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Diogo  Rau", "title": "EVP & Chief Information and Digital Officer", "fiscalYear": 2022, "totalPay": {"raw": 1056809, "fmt": "1.06M", "longFmt": "1,056,809"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alonzo  Weems", "age": 52, "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Dozier", "age": 56, "title": "Executive Vice President of Human Resources & Diversity", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey N. Simmons", "age": 56, "title": "Senior VP & President of Elanco Animal Health", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 1729146, "fmt": "1.73M", "longFmt": "1,729,146"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 1, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1706745600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 735.68, "open": 735.5, "dayLow": 733.61, "dayHigh": 745.7, "regularMarketPreviousClose": 735.68, "regularMarketOpen": 735.5, "regularMarketDayLow": 733.61, "regularMarketDayHigh": 745.7, "dividendRate": 5.2, "dividendYield": 0.0069999998, "exDividendDate": 1707868800, "payoutRatio": 0.8188, "fiveYearAvgDividendYield": 1.49, "beta": 0.316, "trailingPE": 133.36215, "forwardPE": 40.892815, "volume": 2833894, "regularMarketVolume": 2833894, "averageVolume": 3163845, "averageVolume10days": 4401120, "averageDailyVolume10Day": 4401120, "bid": 740.5, "ask": 742.0, "bidSize": 800, "askSize": 800, "marketCap": 702639046656, "fiftyTwoWeekLow": 309.2, "fiftyTwoWeekHigh": 745.7, "priceToSalesTrailing12Months": 20.590698, "fiftyDayAverage": 619.4484, "twoHundredDayAverage": 537.33386, "trailingAnnualDividendRate": 4.52, "trailingAnnualDividendYield": 0.0061439755, "currency": "USD", "fromCurrency": null, "toCurrency": null, "lastMarket": null, "coinMarketCapLink": null, "algorithm": null, "tradeable": false, "enterpriseValue": 683426316288, "profitMargins": 0.15357, "floatShares": 897238830, "sharesOutstanding": 949307008, "sharesShort": 4412216, "sharesShortPriorMonth": 5093399, "sharesShortPreviousMonthDate": 1703808000, "dateShortInterest": 1706659200, "sharesPercentSharesOut": 0.0046, "heldPercentInsiders": 0.00158, "heldPercentInstitutions": 0.84174, "shortRatio": 1.49, "shortPercentOfFloat": 0.0056, "impliedSharesOutstanding": 950883008, "category": null, "bookValue": 12.477, "priceToBook": 59.32195, "fundFamily": null, "legalType": null, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": 0.13, "netIncomeToCommon": 5240399872, "trailingEps": 5.55, "forwardEps": 18.1, "pegRatio": 1.13, "lastSplitFactor": "2:1", "lastSplitDate": 876960000, "enterpriseToRevenue": 20.028, "enterpriseToEbitda": 57.698, "52WeekChange": 1.1123288, "SandP52WeekChange": 0.21495235, "lastDividendValue": 1.13, "lastDividendDate": 1699920000, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "LLY", "underlyingSymbol": "LLY", "shortName": "Eli Lilly and Company", "longName": "Eli Lilly and Company", "firstTradeDateEpochUtc": 76253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7b37be39-dfde-3602-b0e4-4d76cf52143b", "messageBoardId": "finmb_285467", "gmtOffSetMilliseconds": -18000000, "currentPrice": 740.16, "targetHighPrice": 865.0, "targetLowPrice": 430.0, "targetMeanPrice": 730.41, "targetMedianPrice": 785.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 2623500032, "totalCashPerShare": 2.917, "ebitda": 11844866048, "totalDebt": 20331599872, "totalRevenue": 34124099584, "debtToEquity": 179.808, "revenuePerShare": 37.778, "returnOnEquity": 0.47460997, "earningsGrowth": 0.131, "revenueGrowth": 0.281, "grossMargins": 0.79246, "ebitdaMargins": 0.34710997, "operatingMargins": 0.32909, "financialCurrency": "USD"}